Oxygen-depleted hypoxic regions in the tumour are generally resistant to therapies1. Although nanocarriers have been used to deliver drugs, the targeting ratios have been very low. Here, we show that the magneto-aerotactic migration behaviour2 of magnetotactic bacteria3, Magnetococcus marinus strain MC-1 (ref. 4), can be used to transport drug-loaded nanoliposomes into hypoxic regions of the tumour. In their natural environment, MC-1 cells, each containing a chain of magnetic iron-oxide nanocrystals5, tend to swim along local magnetic field lines and towards low oxygen concentrations6 based on a two-state aerotactic sensing system2. We show that when MC-1 cells bearing covalently bound drug-containing nanoliposomes were injected near the tumour in severe combined immunodeficient beige mice and magnetically guided, up to 55% of MC-1 cells penetrated into hypoxic regions of HCT116 colorectal xenografts. Approximately 70 drug-loaded nanoliposomes were attached to each MC-1 cell. Our results suggest that harnessing swarms of microorganisms exhibiting magneto-aerotactic behaviour can significantly improve the therapeutic index of various nanocarriers in tumour hypoxic regions.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Cancer & Metabolism Open Access 09 August 2023
Journal of Hematology & Oncology Open Access 14 July 2023
Journal of Micro-Bio Robotics Open Access 22 April 2023
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225–239 (2007).
Frankel, R. B., Bazylinski, D. A., Johnson, M. S. & Taylor, B. L. Magneto-aerotaxis in marine coccoid bacteria. Biophys. J. 73, 994–1000 (1997).
Blakemore, R. P. Magnetotactic bacteria. Science 190, 377–379 (1975).
Bazilinski, D. A. et al. Magnetococcus marinus gen. nov., sp. nov., a marine, magnetotactic bacterium that represents a novel lineage (Magnetococcaceae fam. nov., Magnetococcales ord. nov.) at the base of the Alphaproteobacteria. Int. J. Syst. Evol. Microbiol. 63, 801–808 (2013).
Bazylinski, D. A., Frankel, R. B. & Jannasch, H. W. Anaerobic magnetite production by a marine, magnetotactic bacterium. Nature 334, 518–519 (1988).
Lefèvre, C. T. et al. Diversity of magneto-aerotactic behaviors and oxygen sensing mechanisms in cultured magnetotactic bacteria. Biophys. J. 107, 527–538 (2014).
Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nature Rev. 4, 437–446 (2004).
Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nature Rev. Cancer 11, 393–410 (2011).
Hong, M., Zhu, S., Jiang, Y., Tang, G. & Pei, Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated liposomes modified with transferrin. J. Control. Rel. 133, 96–102 (2009).
Tannock, I. F., Lee, C. M., Tunggal, J. K., Cowan, D. S. M. & Egorin, M. J. Limited penetration of anticancer drugs through tumor tissue. Clin. Cancer Res. 8, 878–884 (2002).
Patyar, S. et al. Bacteria in cancer therapy: a novel experimental strategy. J. Biomed. Sci. 17, 21 (2010).
Schüler, D. Formation of magnetosomes in magnetotactic bacteria. J. Molec. Microbiol. Biotechnol. 1, 79–86 (1999).
de Lanauze, D., Felfoul, O., Turcot, J.-P., Mohammadi, M. & Martel, S. Three-dimensional remote aggregation and steering of magnetotactic bacteria microrobots for drug delivery applications. Int. J. Robot. Res. 33, 359–374 (2014).
McDonald, D. M. & Baluk, P. Significance of blood vessel leakiness in cancer. Cancer Res. 62, 5381–5385 (2002).
Heldin, C.-H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure—an obstacle in cancer therapy. Nature Rev. Cancer 4, 806–813 (2004).
Taherkhani, S., Mohammadi, M., Daoud, J., Martel, S. & Tabrizian, M. Covalent binding of nanoliposomes to the surface of magnetotactic bacteria acting as self-propelled target delivery agents. ACS Nano 8, 5049–5060 (2014).
Danhier, F., Feron, O. & Préat, V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control Rel. 148, 135–146 (2010).
Harrison, L. B., Chadha, M., Hill, R. J., Hu, K. & Shasha, D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7, 492–508 (2002).
Moeller, B. J., Richardson, R. A. & Dewhirst, M. W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26, 241–248 (2007).
Polyak, B. & Friedman, G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin. Drug Delivery 6, 53–70 (2009).
Rotariu, O. & Strachan, N. J. C. Modelling magnetic carrier particle targeting in the tumor microvasculature for cancer treatment. J. Magn. Magn. Mater. 293, 639–646 (2005).
Martel, S. et al. Automatic navigation of an untethered device in the artery of a living animal using a conventional clinical magnetic resonance imaging system. Appl. Phys. Lett. 90, 114105 (2007).
Dreyfus, R. et al. Microscopic artificial swimmers. Nature 437, 862–865 (2005).
Akin, D. et al. Bacteria-mediated delivery of nanoparticles and cargo into cells. Nature Nanotech. 2, 441–449 (2007).
Jain, R. K. & Forbes, N. S. Can engineered bacteria help control cancer? Proc. Natl Acad. Sci. USA 98, 14748–14750 (2001).
Schübbe, S. et al. Complete genome sequence of the chemolithoautotrophic marine magnetotactic coccus strain MC-1. Appl. Environ. Microbiol. 75, 4835–4852 (2009).
This project was initially supported in part by the Canada Research Chair (CRC) Tier 2 in Micro/Nanosystem Development, Fabrication and Validation and by grants from the National Sciences and Engineering Research Council of Canada (NSERC) and the Province of Québec. This work was primarily supported by the Québec Consortium for Drug Discovery (CQDM) and in part by the Research Chair of École Polytechnique in Nanorobotics, Mitacs, and later by the CRC Tier 1 in Medical Nanorobotics. The magnetotaxis system was built with financial help from the Canada Foundation for Innovation (CFI). Preliminary in vivo results were obtained with the financial help of the US National Institutes of Health (NIH) grant no. R21EB007506 from the National Institute of Biomedical Imaging and Bioengineering. The authors thank J. Caron from CQDM for her involvement in the coordination of the project. R. Gladue from Pfizer, R. M. Garbaccio from Merck & Co. and C. Reimer from AstraZeneca R&D are also thanked for their guidance and insights from the pharmaceutical industry. C.C. Tremblay (NanoRobotics Lab.) helped in determining the number of bacteria in samples and T. Johns (Biomat'x, McGill University) in the preparation of liposomes. The authors thank J. Hinsinger (University of Montreal (UdM), Institute for Research in Immunology and Cancer (IRIC)) and the histological team (UdM, IRIC) for tumour histology preparation and D. Gingras (UdM, IRIC) for transmission electron microscopy.
The authors declare no competing financial interests.
About this article
Cite this article
Felfoul, O., Mohammadi, M., Taherkhani, S. et al. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nature Nanotech 11, 941–947 (2016). https://doi.org/10.1038/nnano.2016.137
This article is cited by
Journal of Hematology & Oncology (2023)
Cancer & Metabolism (2023)
Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field
Nature Communications (2023)
Journal of Micro-Bio Robotics (2023)
Nano Research (2023)